Lucas Wigston, Muktar Ahmed, Zegeye Abebe, Stephen J Pandol, Yohannes Adama Melaku, Savio George Barreto
{"title":"Risk Factor Profiles May Differ Between Younger-Onset and Late-Onset Colorectal Cancer: An Exploratory Analysis of Individual and Cumulative Risk Factors Among the Prostate, Lung, Colorectal and Ovarian Cohort.","authors":"Lucas Wigston, Muktar Ahmed, Zegeye Abebe, Stephen J Pandol, Yohannes Adama Melaku, Savio George Barreto","doi":"10.1111/ajco.70218","DOIUrl":"https://doi.org/10.1111/ajco.70218","url":null,"abstract":"<p><strong>Background: </strong>Rates of young-onset colorectal cancer (CRC) are on the rise globally. Despite this growing burden, the drivers of young-onset adult CRC remain largely unknown.</p><p><strong>Aims: </strong>This study aimed to compare risk factor profiles between younger-onset and late-onset CRC to evaluate differences in their risk factor profiles.</p><p><strong>Methods: </strong>The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial dataset, comprising ∼155,000 US participants including 1219 CRC cases, was analysed. Participants were stratified by age (≤59 vs. ≥60 years). Associations of demographic, clinical and behavioural risk factors with CRC were computed using multivariable Cox regression with the multiplicative interaction of exposures. Reduced rank regression was used to derive dietary patterns (DPs).</p><p><strong>Results: </strong>Among the ≤59-year cohort, no individual risk factor (excluding age) was independently associated with the risk of CRC. However, the multiplicative effect of hypertension and smoking had a nominal association with younger-onset CRC (p = 0.047). In contrast, in the ≥60-year cohort, individual (sex, body mass index, diabetes and alcohol) as well as combinations of risk factors were associated with CRC. Significant DPs appeared exclusively to impact the risk of CRC in the ≥60-year cohort. However, no interactions remained significant following correction for multiple testing; findings should be interpreted as hypothesis-generating.</p><p><strong>Conclusions: </strong>These findings suggest that the drivers of CRC in younger individuals may be different from their older counterparts. These exploratory findings offer novel insight into CRC risk in the young and highlight the need to reconsider interactions between CRC risk factors.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Omar Abu Saadeh, Hugo C Temperley, Niall J O'Sullivan, Benjamin M Mac Curtain, Kevin P Sheahan, Julian Soares, Michael E Kelly, Satish Warrier, Zi Qin Ng
{"title":"Transarterial Chemoembolization and Chemo-Immunoembolization in Locally Advanced Rectal Cancer: An Updated Systematic Review.","authors":"Omar Abu Saadeh, Hugo C Temperley, Niall J O'Sullivan, Benjamin M Mac Curtain, Kevin P Sheahan, Julian Soares, Michael E Kelly, Satish Warrier, Zi Qin Ng","doi":"10.1111/ajco.70225","DOIUrl":"https://doi.org/10.1111/ajco.70225","url":null,"abstract":"<p><p>Locally advanced rectal cancer (LARC) often requires aggressive multimodal therapy, yet pathological complete response (pCR) to standard chemoradiotherapy remains low. Transarterial chemoembolization (TACE) enables targeted locoregional delivery of chemotherapy to tumor-feeding arteries, and its recent extension, chemo-immunoembolization, permits intraarterial delivery of immune checkpoint inhibitors. This updated systematic review searched MEDLINE, EMBASE, and Web of Science from inception to June 2026 for studies of TACE or transcatheter rectal arterial chemoembolization (TRACE) in LARC, with quality appraised using the Newcastle-Ottawa Scale. Nine studies encompassing 822 patients, 582 of whom received TACE or TRACE, were included, predominantly from China; one further trial is ongoing. pCR rates ranged from 10% to 44.74%. In comparative studies, TRACE with oxaliplatin was associated with lower tumor regression grade 3 (TRG3) rates, reaching significance in the largest comparison, and with a survival benefit in an exploratory TRG3 subgroup analysis, suggesting a possible role in chemoradiotherapy-resistant disease. The highest pCR occurred in a phase II trial of intra-arterial tislelizumab plus TACE in mismatch repair-proficient LARC, with no grade 3-4 immune-related adverse events. Major complications were uncommon. TACE may improve pathological response with an acceptable safety profile in LARC, although comparative evidence is limited and non-randomized; CIETAI provides first-in-human proof-of-concept for intra-arterial delivery of immunotherapy.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Evon Jude, Sarah Jaboury, Qing Ze Fang, Josephine Stewart, Frances Barnett, Bianca Devitt, Belinda Yeo
{"title":"Real-World Toxicity and Outcomes of KEYNOTE-522-Style Neoadjuvant Pembrolizumab for Triple-Negative Breast Cancer in Australia.","authors":"Evon Jude, Sarah Jaboury, Qing Ze Fang, Josephine Stewart, Frances Barnett, Bianca Devitt, Belinda Yeo","doi":"10.1111/ajco.70223","DOIUrl":"https://doi.org/10.1111/ajco.70223","url":null,"abstract":"<p><strong>Background: </strong>Following the KEYNOTE-522 trial, neoadjuvant pembrolizumab with chemotherapy (chemo-IO) became the standard of care in Australia for patients with triple-negative breast cancer (TNBC). In KEYNOTE-522, patients achieved significantly higher pathological complete response (pCR) at the cost of more immune-related adverse events (irAEs). The objective of this study was to collect real-world data on the use of neoadjuvant pembrolizumab in patients with TNBC to identify patterns of irAEs and outcomes.</p><p><strong>Patients and methods: </strong>Retrospective data were collected across three tertiary hospitals in Melbourne, Australia, for all patients diagnosed with TNBC who commenced neoadjuvant pembrolizumab combined with chemotherapy from December 2022 until August 2024. Data were collected until October 30, 2025, and included baseline demographics, neoadjuvant treatment and irAEs, breast surgery, and pCR rates, and were analyzed using descriptive statistics and Kaplan-Meier estimates.</p><p><strong>Results: </strong>Fifty-four female patients received neoadjuvant chemo-IO (median age = 52 years, median follow-up = 26 months). Three patients had a history of autoimmune disease. 69% had nodal involvement at diagnosis. 65% of patients experienced at least one irAE, most commonly thyroid dysfunction (28%), adrenal dysfunction (20%), colitis (9%), and arthralgias (9%). 43% of those with irAEs were hospitalized, 9% required intensive care, and 51% have ongoing sequelae. The median time to onset of irAE was 84 days (22-505 days). 50% achieved pCR. There was no difference in pCR between those who experienced an irAE and those who did not (p = 0.081).</p><p><strong>Conclusion: </strong>Real-world data show a higher proportion of irAEs associated with neoadjuvant pembrolizumab in TNBC than the original KEYNOTE-522 study, with a notable proportion leading to hospitalization. This information can be used to guide shared decision-making.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Highlighted Lectures and Awards","authors":"","doi":"10.1111/ajco.70185","DOIUrl":"https://doi.org/10.1111/ajco.70185","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 S5","pages":"7-8"},"PeriodicalIF":2.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149311469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}